Vascular endothelial growth factor (VEGF) signaling in tumor progression

Critical Reviews in Oncology/Hematology

Volumn 62, Issue 3, 2007, Pages 179-213

  Roskoski Jr , Robert ^a  

^a Blue Ridge Institute for Medical Research   (United States)

Author keywords

Angiogenesis; Hypoxia; Neuropilin; Proteolysis; Receptor protein tyrosine kinase; Vasculogenesis

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ANGIOGENIC FACTOR; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; EPHRIN A1; EPHRIN B1; EPHRIN B2; EPIDERMAL GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 8; LEPTIN; NEUROPILIN 1; NEUROPILIN 2; PLACENTAL GROWTH FACTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

AMINO ACID SEQUENCE; CELL SURVIVAL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; HUMAN; HYDROXYLATION; HYPOXIA; METASTASIS; MORPHOLOGY; NONHUMAN; ONCOGENE; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; STIMULATION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; UNINDEXED SEQUENCE; UPREGULATION;

HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEUROPILINS; ONCOGENES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33947370773     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.01.006     Document Type: Review

References (286)

1. Cines D.B., Pollak E.S., Buck C.A., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91 (1998) 3527-3561
2. Dvorak H.F. Angiogenesis: update 2005. J Thromb Haemost 3 (2005) 1835-1842
3. Coultas L., Chawengsaksophak K., and Rossant J. Endothelial cells and VEGF in vascular development. Nature 438 (2005) 937-945
4. Aghi M., and Chiocca E.A. Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Mol Ther 12 (2005) 994-1005
5. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
6. Zammaretti P., and Zisch A.H. Adult 'endothelial progenitor cells'. Renewing vasculature. Int J Biochem Cell Biol 37 (2005) 493-503
7. Ziegelhoeffer T., Fernandez B., Kostin S., et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 94 (2004) 230-238
8. Folkman J., Heymach J., and Kalluri R.T. Tumor angiogenesis. In: Kufe D.W., Bast Jr. R.C., Hite W.H., Hong W.K., Pollack R.E., Weichselbaum R.R., et al. (Eds). Cancer medicine. 7th ed. (2006), B.C. Decker, Hamilton, Ontario 157-191
9. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
10. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
11. Eklund L., and Olsen B.R. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 312 (2006) 630-641
12. Heroult M., Schaffner F., and Augustin H.G. Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 312 (2006) 642-650
13. Relf M., LeJeune S., Scott P.A., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57 (1997) 963-969
14. Nyberg P., Xie L., and Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 65 (2005) 3967-3979
15. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
16. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
17. Dameron K.M., Volpert O.V., Tainsky M.A., and Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265 (1994) 1582-1584
18. Pepper M.S. Manipulating angiogenesis. From basic science to the bedside. Arterioscler Thromb Vasc Biol 17 (1997) 605-619
19. Auguste P., Lemiere S., Larrieu-Lahargue F., and Bikfalvi A. Molecular mechanisms of tumor vascularization. Crit Rev Oncol Hematol 54 (2005) 53-61
20. Patan S., Munn L.L., and Jain R.K. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res 51 (1996) 260-272
21. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 (1999) 1994-1998
22. Chang Y.S., di Tomaso E., McDonald D.M., Jones R., Jain R.K., and Munn L.L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97 (2000) 14608-14613
23. Maniotis A.J., Folberg R., Hess A., et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155 (1999) 739-752
24. Hendrix M.J., Seftor E.A., Hess A.R., and Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3 (2003) 411-421
25. Less J.R., Skalak T.C., Sevick E.M., and Jain R.K. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 51 (1991) 265-273
26. Algire G.H., and Chalkley H.W. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 6 (1945) 73-85
27. Jain R.K. Molecular regulation of vessel maturation. Nature Med 9 (2003) 685-693
28. Gerwins P., Skoldenberg E., and Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 34 (2000) 185-194
29. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., and De Bruijn E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56 (2004) 549-580
30. Robinson C.J., and Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114 (2001) 853-865
31. Kärpänen T., Heckman C.A., Keskitalo S., et al. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J 20 (2006) 1462-1472
32. Plöuet J., and Moukadiri H.J. Characterization of the receptors for vasculotropin on bovine adrenal cortex-derived capillary endothelial cells. J Biol Chem 265 (1990) 22071-22075
33. Vaisman N., Gospodarowicz D., and Neufeld G. Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 265 (1990) 19461-19466
34. Shibuya M., Yamaguchi S., Yamane A., et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5 (1990) 519-524
35. Matthews W., Jordan C.T., Gavin M., Jenkins N.A., Copeland N.G., and Lemischka I.R. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 88 (1991) 9026-9030
36. Terman B.I., Carrion M.E., Kovacs E., Rasmussen B.A., Eddy R.L., and Shows T.B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6 (1991) 1677-1683
37. Terman B.I., Dougher-Vermazen M., Carrion M.E., et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187 (1992) 1579-1586
38. Pajusola K., Aprelikova O., Korhonen J., et al. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res 52 (1992) 5738-5743
39. Fantl W.J., Johnson D.E., and Williams L.T. Signalling by receptor tyrosine kinases. Annu Rev Biochem 62 (1993) 453-481
40. Hubbard S.R., and Till J.H. Protein tyrosine kinase structure and function. Annu Rev Biochem 69 (2000) 373-398
41. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., and Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
42. Ferrara N., and Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161 (1989) 851-858
43. Gospodarowicz D., Abraham J.A., and Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 86 (1989) 7311-7315
44. Connolly D.T., Heuvelman D.M., Nelson R., et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84 (1989) 1470-1478
45. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50 (1990) 1774-1778
46. Plouët J., Schilling J., and Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 8 (1989) 3801-3806
47. Levy A.P., Tamargo R., Brem H., and Nathans D. An endothelial cell growth factor from the mouse neuroblastoma cell line NB41. Growth Factors 2 (1989) 9-19
48. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
49. Keck P.J., Hauser S.D., Krivi G., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246 (1989) 1309-1312
50. Conn G., Bayne M.L., Soderman D.D., et al. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 87 (1990) 2628-2632
51. Alon T., Hemo I., Itin A., Pe'er J., Stone J., and Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1 (1995) 1024-1028
52. Gerber H.P., McMurtrey A., Kowalski J., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273 (1998) 30336-30343
53. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., and Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269 (1994) 26988-26995
54. Clauss M., Gerlach M., Gerlach H., et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172 (1990) 1535-1545
55. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., and Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87 (1996) 3336-3343
56. Tischer E., Mitchell R., Hartman T., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266 (1991) 11947-11954
57. Guttmann-Raviv N., Kessler O., Shraga-Heled N., Lange T., Herzog Y., and Neufeld G. The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett 231 (2006) 1-11
58. Berse B., Brown L.F., Van de Water L., Dvorak H.F., and Senger D.R. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3 (1992) 211-220
59. Breier G., Albrecht U., Sterrer S., and Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114 (1992) 521-532
60. Ng Y.S., Rohan R., Sunday M.E., Demello D.E., and D'Amore P.A. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 220 (2001) 112-121
61. Maharaj A.S., Saint-Geniez M., Maldonado A.E., and D'Amore P.A. Vascular endothelial growth factor localization in the adult. Am J Pathol 168 (2006) 639-648
62. Carmeliet P., Ferreira V., Breier G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
63. Ferrara N., Carver-Moore K., Chen H., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996) 439-442
64. Muller Y.A., Li B., Christinger H.W., Wells J.A., Cunningham B.C., and de Vos A.M. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA 94 (1997) 7192-7197
65. Olofsson B., Pajusola K., von Euler G., Chilov D., Alitalo K., and Eriksson U. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem 271 (1996) 19310-19317
66. Iyer S., Scotney P.D., Nash A.D., and Ravi Acharya K. Crystal structure of human vascular endothelial growth factor-B: identification of amino acids important for receptor binding. J Mol Biol 359 (2006) 76-85
67. Lagercrantz J., Farnebo F., Larsson C., Tvrdik T., Weber G., and Piehl F. A comparative study of the expression patterns for vegf, vegf-b/vrf and vegf-c in the developing and adult mouse. Biochim Biophys Acta 1398 (1998) 157-163
68. Salven P., Lymboussaki A., Heikkila P., et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153 (1998) 103-108
69. Tammela T., Enholm B., Alitalo K., and Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 65 (2005) 550-563
70. Aase K., von Euler G., Li X., et al. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation 104 (2001) 358-364
71. Joukov V., Pajusola K., Kaipainen A., et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15 (1996) 1751-1758
72. Joukov V., Sorsa T., Kumar V., et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16 (1997) 3898-3911
73. Zhou A., Webb G., Zhu X., and Steiner D.F. Proteolytic processing in the secretory pathway. J Biol Chem 274 (1999) 20745-20748
74. Siegfried G., Basak A., Cromlish J.A., et al. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 111 (2003) 1723-1732
75. Chilov D., Kukk E., Taira S., et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 272 (1997) 25176-25183
76. Kukk E., Lymboussaki A., Taira S., et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122 (1996) 3829-3837
77. Lymboussaki A., Olofsson B., Eriksson U., and Alitalo K. Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia. Circ Res 85 (1999) 992-999
78. Su J.L., Yang P.C., Shih J.Y., et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 9 (2006) 209-223
79. Shida A., Fujioka S., Kobayashi K., et al. Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. Int J Clin Oncol 11 (2006) 38-43
80. Karkkainen M.J., Haiko P., Sainio K., et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5 (2004) 74-80
81. Stacker S.A., Stenvers K., Caesar C., et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem 274 (1999) 32127-32136
82. Yamada Y., Nezu J., Shimane M., and Hirata Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 42 (1997) 483-488
83. Rocchigiani M., Lestingi M., Luddi A., et al. Human FIGF: cloning, gene structure, and mapping to chromosome Xp22.1 between the PIGA and the GRPR genes. Genomics 47 (1998) 207-216
84. Baldwin M.E., Halford M.M., Roufail S., et al. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol 25 (2005) 2441-2449
85. Achen M.G., Jeltsch M., Kukk E., et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95 (1998) 548-553
86. Nakamura Y., Yasuoka H., Tsujimoto M., et al. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. Clin Cancer Res 9 (2003) 716-721
87. White J.D., Hewett P.W., Kosuge D., et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 62 (2002) 1669-1675
88. Yasuoka H., Nakamura Y., Zuo H., et al. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 18 (2005) 1127-1133
89. Van Trappen P.O., Steele D., Lowe D.G., et al. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 201 (2003) 544-554
90. Debinski W., Slagle-Webb B., Achen M.G., et al. VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. Mol Med 7 (2001) 598-608
91. Achen M.G., Williams R.A., Minekus M.P., et al. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol 193 (2001) 147-154
92. Funaki H., Nishimura G., Harada S., et al. Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma. Oncology 64 (2003) 416-422
93. Niki T., Iba S., Tokunou M., Yamada T., Matsuno Y., and Hirohashi S. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 6 (2000) 2431-2439
94. Yokoyama Y., Charnock-Jones D.S., Licence D., et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 88 (2003) 237-244
95. Maglione D., Guerriero V., Viglietto G., Delli-Bovi P., and Persico M.G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88 (1991) 9267-9271
96. Iyer S., Leonidas D.D., Swaminathan G.J., et al. The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 Å resolution. J Biol Chem 276 (2001) 12153-12161
97. Maglione D., Guerriero V., Viglietto G., et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 8 (1993) 925-931
98. Cao Y., Ji W.R., Qi P., Rosin A., and Cao Y. Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. Biochem Biophys Res Commun 235 (1997) 493-498
99. Yang W., Ahn H., Hinrichs M., Torry R.J., and Torry D.S. Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells. J Reprod Immunol 60 (2003) 53-60
100. Parr C., Watkins G., Boulton M., Cai J., and Jiang W.G. Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 41 (2005) 2819-2827
101. Chen C.N., Hsieh F.J., Cheng Y.M., et al. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 213 (2004) 73-82
102. Matsumoto K., Suzuki K., Koike H., et al. Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia. Anticancer Res 23 (2003) 3767-3773
103. Zhang L., Chen J., Ke Y., Mansel R.E., and Jiang W.G. Expression of placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 3 (2005) 68
104. Iwama H., Uemura S., Naya N., et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol 47 (2006) 1559-1567
105. Persico M.G., Vincenti V., and DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol 237 (1999) 31-40
106. Feeney S.A., Simpson D.A., Gardiner T.A., Boyle C., Jamison P., and Stitt A.W. Role of vascular endothelial growth factor and placental growth factors during retinal vascular development and hyaloid regression. Invest Ophthalmol Vis Sci 44 (2003) 839-847
107. Failla C.M., Odorisio T., Cianfarani F., Schietroma C., Puddu P., and Zambruno G. Placenta growth factor is induced in human keratinocytes during wound healing. J Invest Dermatol 115 (2000) 388-395
108. Odorisio T., Cianfarani F., Failla C.M., and Zambruno G. The placenta growth factor in skin angiogenesis. J Dermatol Sci 41 (2006) 11-19
109. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7 (2001) 575-583
110. Meyer M., Clauss M., Lepple-Wienhues A., et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18 (1999) 363-374
111. Park J.E., Chen H.H., Winer J., Houck K.A., and Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269 (1994) 25646-25654
112. Olofsson B., Korpelainen E., Pepper M.S., et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 95 (1998) 11709-11714
113. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., and Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255 (1992) 989-991
114. Peters K.G., De Vries C., and Williams L.T. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci USA 90 (1993) 8915-8919
115. Quinn T.P., Peters K.G., De Vries C., Ferrara N., and Williams L.T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 90 (1993) 7533-7537
116. Kendall R.L., and Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90 (1993) 10705-10709
117. Clark D.E., Smith S.K., He Y., et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 59 (1998) 1540-1548
118. Robinson C.J., Johnson D.D., Chang E.Y., Armstrong D.M., and Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 195 (2006) 255-259
119. Ito N., Wernstedt C., Engstrom U., and Claesson-Welsh L. Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules. J Biol Chem 273 (1998) 23410-23418
120. Sawano A., Takahashi T., Yamaguchi S., and Shibuya M. The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCγ. Biochem Biophys Res Commun 238 (1997) 487-491
121. Olsson A.K., Dimberg A., Kreuger J., and Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 7 (2006) 359-371
122. Autiero M., Waltenberger J., Communi D., et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9 (2003) 936-943
123. Wiesmann C., Fuh G., Christinger H.W., Eigenbrot C., Wells J.A., and de Vos A.M. Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91 (1997) 695-704
124. Christinger H.W., Fuh G., de Vos A.M., and Wiesmann C. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J Biol Chem 279 (2004) 10382-10388
125. Gille H., Kowalski J., Li B., et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). J Biol Chem 276 (2001) 3222-3230
126. Takahashi T., Yamaguchi S., Chida K., and Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. EMBO J 20 (2001) 2768-2778
127. Bernatchez P.N., Soker S., and Sirois M.G. Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J Biol Chem 274 (1999) 31047-31054
128. Matsumoto T., Bohman S., Dixelius J., et al. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J 24 (2005) 2342-2353
129. Shibuya M., and Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312 (2006) 549-560
130. Kendall R.L., Rutledge R.Z., Mao X., Tebben A.J., Hungate R.W., and Thomas K.A. Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues. J Biol Chem 274 (1999) 6453-6460
131. Holmqvist K., Cross M.J., Rolny C., et al. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 279 (2004) 22267-22275
132. Ebos J.M., Bocci G., Man S., et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2 (2004) 315-326
133. Gerber H.P., Condorelli F., Park J., and Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 272 (1997) 23659-23667
134. Pajusola K., Aprelikova O., Korhonen J., et al. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res 52 (1992) 5738-5743 (Erratum in: Cancer Res 1993;53:3845)
135. Galland F., Karamysheva A., Pebusque M.J., et al. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene 8 (1993) 1233-1240
136. Kaipainen A., Korhonen J., Mustonen T., et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 92 (1995) 3566-3570
137. Nilsson I., Rolny C., Wu Y., et al. Vascular endothelial growth factor receptor-3 in hypoxia-induced vascular development. FASEB J 18 (2004) 1507-1515
138. Dixelius J., Makinen T., Wirzenius M., et al. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem 278 (2003) 40973-40979
139. Alam A., Herault J.P., Barron P., et al. Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochem Biophys Res Commun 324 (2004) 909-915
140. Soker S., Takashima S., Miao H.Q., Neufeld G., and Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92 (1998) 735-745
141. Takagi S., Hirata T., Agata K., Mochii M., Eguchi G., and Fujisawa H. The A5 antigen, a candidate for the neuronal recognition molecule, has homologies to complement components and coagulation factors. Neuron 7 (1991) 295-307
142. Takagi S., Kasuya Y., Shimizu M., et al. Expression of a cell adhesion molecule, neuropilin, in the developing chick nervous system. Dev Biol 170 (1995) 207-222
143. Chen H., Bagri A., Zupicich J.A., et al. Neuropilin-2 regulates the development of selective cranial and sensory nerves and hippocampal mossy fiber projections. Neuron 25 (2000) 43-56
144. Bielenberg D.R., Pettaway C.A., Takashima S., and Klagsbrun M. Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res 312 (2006) 584-593
145. Ellis L.M. The role of neuropilins in cancer. Mol Cancer Ther 5 (2006) 1099-1107
146. Semaphorin nomenclature committee. Unified nomenclature for the semaphorins/collapsins. Cell 97 (1999) 551-552
147. Neufeld G., Kessler O., and Herzog Y. The interaction of neuropilin-1 and neuropilin-2 with tyrosine-kinase receptors for VEGF. Adv Exp Med Biol 515 (2002) 81-90
148. Migdal M., Huppertz B., Tessler S., et al. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 273 (1998) 22272-22278
149. Makinen T., Olofsson B., Kärpänen T., et al. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem 274 (1999) 21217-21222
150. Gluzman-Poltorak Z., Cohen T., Herzog Y., and Neufeld G. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165. J Biol Chem 275 (2000) 18040-18045 (Erratum in: J Biol Chem; 2000;275:29922)
151. Karkkainen M.J., Saaristo A., Jussila L., et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA 98 (2001) 12677-12682
152. Mamluk R., Gechtman Z., Kutcher M.E., Gasiunas N., Gallagher J., and Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem 277 (2002) 24818-24825
153. Takahashi T., Nakamura F., Jin Z., Kalb R.G., and Strittmatter S.M. Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors. Nat Neurosci 1 (1998) 487-493
154. Favier B., Alam A., Barron P., et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 108 (2006) 1243-1250
155. Ding H., Wu X., Roncari L., et al. Expression and regulation of neuropilin-1 in human astrocytomas. Int J Cancer 88 (2000) 584-592
156. Sanchez-Carbayo M., Socci N.D., Lozano J.J., et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 163 (2003) 505-516
157. Ochiumi T., Kitadai Y., Tanaka S., Akagi M., Yoshihara M., and Chayama K. Neuropilin-1 is involved in regulation of apoptosis and migration of human colon cancer. Int J Oncol 29 (2006) 105-116
158. Hansel D.E., Wilentz R.E., Yeo C.J., Schulick R.D., Montgomery E., and Maitra A. Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract. Am J Surg Pathol 28 (2004) 347-356
159. Rieger J., Wick W., and Weller M. Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins. Glia 42 (2003) 379-389
160. Lacal P.M., Failla C.M., Pagani E., et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 115 (2000) 1000-1007
161. Beierle E.A., Dai W., Langham Jr. M.R., Copeland III E.M., and Chen M.K. VEGF receptors are differentially expressed by neuroblastoma cells in culture. J Pediatr Surg 38 (2003) 514-521
162. Lantuejoul S., Constantin B., Drabkin H., Brambilla C., Roche J., and Brambilla E. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol 200 (2003) 336-347
163. Parikh A.A., Liu W.B., Fan F., et al. Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer 98 (2003) 720-729
164. Fukahi K., Fukasawa M., Neufeld G., Itakura J., and Korc M. Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. Clin Cancer Res 10 (2004) 581-590
165. Miao H.Q., Lee P., Lin H., Soker S., and Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 14 (2000) 2532-2539
166. Latil A., Bieche I., Pesche S., et al. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer 89 (2000) 167-171
167. Akagi M., Kawaguchi M., Liu W., et al. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br J Cancer 88 (2003) 796-802
168. Parikh A.A., Fan F., Liu W.B., et al. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol 164 (2004) 2139-2151
169. Wey J.S., Gray M.J., Fan F., et al. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer 93 (2005) 233-241
170. Shi X., Friess H., Kleeff J., Ozawa F., and Buchler M.W. Pancreatic cancer: factors regulating tumor development, maintenance and metastasis. Pancreatology 1 (2001) 517-524
171. Barr M.P., Byrne A.M., Duffy A.M., et al. A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells. Br J Cancer 92 (2005) 328-333
172. Castro-Rivera E., Ran S., Thorpe P., and Minna J.D. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci USA 101 (2004) 11432-11437
173. Nasarre P., Constantin B., Rouhaud L., et al. Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading. Neoplasia 5 (2003) 83-92
174. Nasarre P., Kusy S., Constantin B., et al. Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia 7 (2005) 180-189
175. Roche J., Boldog F., Robinson M., et al. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12 (1996) 1289-1997
176. Sekido Y., Bader S., Latif F., et al. Human semaphorins A (V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci USA 93 (1996) 4120-4125
177. Xiang R.H., Hensel C.H., Garcia D.K., et al. Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer. Genomics 32 (1996) 39-48
178. Kusy S., Nasarre P., Chan D., et al. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia 7 (2005) 457-465
179. Kessler O., Shraga-Heled N., Lange T., et al. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64 (2004) 1008-1015
180. Gagnon M.L., Bielenberg D.R., Gechtman Z., et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc Natl Acad Sci USA 97 (2000) 2573-2578
181. Oh H., Takagi H., Otani A., et al. Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis. Proc Natl Acad Sci USA 99 (2002) 383-388
182. 2 activity. Mol Vis 10 (2004) 341-350
183. Fujita H., Zhang B., Sato K., Tanaka J., and Sakanaka M. Expressions of neuropilin-1, neuropilin-2 and semaphorin 3A mRNA in the rat brain after middle cerebral artery occlusion. Brain Res 914 (2001) 1-14
184. Fong G.H., Rossant J., Gertsenstein M., and Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376 (1995) 66-70
185. Hiratsuka S., Minowa O., Kuno J., Noda T., and Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95 (1998) 9349-9354
186. Shalaby F., Rossant J., Yamaguchi T.P., et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376 (1995) 62-66
187. Dumont D.J., Jussila L., Taipale J., et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282 (1998) 946-949
188. Kawasaki T., Kitsukawa T., Bekku Y., et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 126 (1999) 4895-4902
189. Kitsukawa T., Shimono A., Kawakami A., Kondoh H., and Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 121 (1995) 4309-4318
190. Kitsukawa T., Shimizu M., Sanbo M., et al. Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron 19 (1997) 995-1005
191. Chen H., Chedotal A., He Z., Goodman C.S., and Tessier-Lavigne M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron 19 (1997) 547-559 (Erratum in: Neuron 1997;19:559)
192. Giger R.J., Cloutier J.F., Sahay A., et al. Neuropilin-2 is required in vivo for selective axon guidance responses to secreted semaphorins. Neuron 25 (2000) 29-41
193. Yuan L., Moyon D., Pardanaud L., et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129 (2002) 4797-4806
194. Takashima S., Kitakaze M., Asakura M., et al. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci USA 99 (2002) 3657-3662
195. Houck K.A., Leung D.W., Rowland A.M., Winer J., and Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267 (1992) 26031-26037
196. Flaumenhaft R., and Rifkin D.B. The extracellular regulation of growth factor action. Mol Biol Cell 3 (1992) 1057-1065
197. Mignatti P., and Rifkin D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73 (1993) 161-195
198. Pepper M.S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21 (2001) 1104-1117
199. Duffy M.J. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10 (2004) 39-49
200. Overall C.M., and Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6 (2006) 227-239
201. Roy R., Zhang B., and Moses M.A. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res 312 (2006) 608-622
202. Greene J., Wang M., Liu Y.E., Raymond L.A., Rosen C., and Shi Y.E. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 271 (1996) 30375-30380
203. Keyt B.A., Berleau L.T., Nguyen H.V., et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271 (1996) 7788-7795
204. Whitaker G.B., Limberg B.J., and Rosenbaum J.S. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). J Biol Chem 276 (2001) 25520-25531
205. Lauer G., Sollberg S., Cole M., et al. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J Invest Dermatol 115 (2000) 12-18
206. Roth D., Piekarek M., Paulsson M., et al. Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair. Am J Pathol 168 (2006) 670-684
207. Plouët J., Moro F., Bertagnolli S., et al. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 272 (1997) 13390-13396
208. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., and Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169 (2005) 681-691
209. 165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. J Biol Chem 280 (2005) 31508-31515
210. Carmeliet P., Ng Y.S., Nuyens D., et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 5 (1999) 495-502
211. Stalmans I., Ng Y.S., Rohan R., et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 109 (2002) 327-336
212. Carmeliet P. Blood vessels and nerves: common signals, pathways and diseases. Nat Rev Genet 4 (2003) 710-720
213. Manalo D.J., Rowan A., Lavoie T., et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105 (2005) 659-669
214. Hirota K., and Semenza G.L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 59 (2006) 15-26
215. Zhou J., Schmid T., Schnitzer S., and Brune B. Tumor hypoxia and cancer progression. Cancer Lett 237 (2006) 10-21
216. Berra E., Ginouves A., and Pouyssegur J. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep 7 (2006) 41-45
217. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
218. Berra E., Richard D.E., Gothie E., and Pouyssegur J. HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1α degradation. FEBS Lett 491 (2001) 85-90
219. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 22 (2003) 4082-4090
220. Takeda K., Ho V.C., Takeda H., Duan L.J., Nagy A., and Fong G.H. Placental but not heart defects are associated with elevated hypoxia-inducible factor α levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol 26 (2006) 8336-8346
221. Koivunen P., Hirsila M., Gunzler V., Kivirikko K.I., and Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 279 (2004) 9899-9904
222. Sendroy Jr. J., Dillon R.T., and Van Slyke D.D. Studies of gas and electrolyte equilibria in blood. XIX. The solubility and physical state of uncombined oxygen in blood. J Biol Chem 105 (1934) 597-632
223. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 (1996) 4604-4613
224. Goldman C.K., Kim J., Wong W.L., King V., Brock T., and Gillespie G.Y. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4 (1993) 121-133
225. Ongusaha P.P., Kwak J.C., Zwible A.J., et al. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 64 (2004) 5283-5290
226. Finkenzeller G., Marme D., Weich H.A., and Hug H. Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res 52 (1992) 4821-4823
227. Pertovaara L., Kaipainen A., Mustonen T., et al. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 269 (1994) 6271-6274
228. Benckert C., Jonas S., Cramer T., et al. Transforming growth factor β1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63 (2003) 1083-1092
229. Sugano Y., Matsuzaki K., Tahashi Y., et al. Distortion of autocrine transforming growth factor β signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells. Oncogene 22 (2003) 2309-2321
230. Wagner K., Peters M., Scholz A., et al. Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells. Gastroenterology 126 (2004) 1828-1843
231. Ryuto M., Ono M., Izumi H., et al. Induction of vascular endothelial growth factor by tumor necrosis factor α in human glioma cells. Possible roles of SP-1. J Biol Chem 271 (1996) 28220-28228
232. Kawaguchi M., Akagi M., Gray M.J., Liu W., Fan F., and Ellis L.M. Regulation of vascular endothelial growth factor expression in human gastric cancer cells by interleukin-1β. Surgery 136 (2004) 686-692
233. Cohen T., Nahari D., Cerem L.W., Neufeld G., and Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271 (1996) 736-741
234. Huang S.P., Wu M.S., Shun C.T., et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 11 (2004) 517-527
235. Bermont L., Lamielle F., Lorchel F., et al. Insulin up-regulates vascular endothelial growth factor and stabilizes its messengers in endometrial adenocarcinoma cells. J Clin Endocrinol Metab 86 (2001) 363-368
236. Warren R.S., Yuan H., Matli M.R., Ferrara N., and Donner D.B. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 271 (1996) 29483-29488
237. Wang J., Luo F., Lu J.J., Chen P.K., Liu P., and Zheng W. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer 97 (2002) 163-167
238. Haggstrom S., Lissbrant I.F., Bergh A., and Damber J.E. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J Urol 161 (1999) 1620-1625
239. Lissbrant I.F., Hammarsten P., Lissbrant E., Ferrara N., Rudolfsson S.H., and Bergh A. Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3) IgG inhibits testosterone-stimulated prostate growth in castrated mice. Prostate 58 (2004) 57-65
240. Hyder S.M., Murthy L., and Stancel G.M. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 58 (1998) 392-395
241. Liang Y., Wu J., Stancel G.M., and Hyder S.M. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. J Steroid Biochem Mol Biol 93 (2005) 173-182
242. Sherr C.J. Principles of tumor suppression. Cell 116 (2004) 235-246
243. Zhang L., Yu D., Hu M., et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 60 (2000) 3655-3661
244. Zhang Z., Li M., Rayburn E.R., Hill D.L., Zhang R., and Wang H. Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. Am J Pharmacogenomics 5 (2005) 173-190
245. Rak J., Filmus J., Finkenzeller G., Grugel S., Marme D., and Kerbel R.S. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14 (1995) 263-277
246. Qi M., and Elion E.A. MAP kinase pathways. J Cell Sci 118 (2005) 3569-3572
247. Thompson T.C., Southgate J., Kitchener G., and Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56 (1989) 917-930
248. Grugel S., Finkenzeller G., Weindel K., Barleon B., and Marme D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 270 (1995) 25915-25919
249. Sassone-Corsi P., Ransone L.J., Lamph W.W., and Verma I.M. Direct interaction between fos and jun nuclear oncoproteins: role of the 'leucine zipper' domain. Nature 336 (1988) 692-695
250. Whitmarsh A.J., and Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74 (1996) 589-607
251. Xie K., Wei D., Shi Q., and Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 15 (2004) 297-324
252. Rak J., Mitsuhashi Y., Bayko L., et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55 (1995) 4575-4580
253. Arbiser J.L., Moses M.A., Fernandez C.A., et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 94 (1997) 861-866
254. Kranenburg O., Gebbink M.F., and Voest E.E. Stimulation of angiogenesis by Ras proteins. Biochim Biophys Acta 1654 (2004) 23-37
255. Konishi T., Huang C.L., Adachi M., et al. The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers. Int J Oncol 16 (2000) 501-511
256. Ikeda N., Nakajima Y., Sho M., et al. The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma. Cancer 92 (2001) 488-499
257. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 3 (2003) 643-651
258. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
259. Dailey L., Ambrosetti D., Mansukhani A., and Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 16 (2005) 233-247
260. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
261. Dvorak H.F., Sioussat T.M., Brown L.F., et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 174 (1991) 1275-1278
262. Jubb A.M., Oates A.J., Holden S., and Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 6 (2006) 626-635
263. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
264. Muller Y.A., Chen Y., Christinger H.W., et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface. Structure 6 (1998) 1153-1167
265. Liang W.C., Wu X., Peale F.V., et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281 (2006) 951-961
266. Jubb A.M., Hurwitz H.I., Bai W., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24 (2006) 217-227
267. Ferrara N., Hillan K.J., and Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333 (2005) 328-335
268. Amato R.J. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16 (2005) 7-15
269. Ranieri G., Patruno R., Ruggieri E., Montemurro S., Valerio P., and Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13 (2006) 1845-1857
270. Ruegg C., Hasmim M., Lejeune F.J., and Alghisi G.C. Antiangiogenic peptides and proteins: From experimental tools to clinical drugs. Biochim Biophys Acta 1765 (2006) 155-177
271. de Castro Junior G., Puglisi F., de Azambuja E., El Saghir N.S., and Awada A. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the "do ut des" paradigm). Crit Rev Oncol Hematol 59 (2006) 40-50
272. Gridelli C., Rossi A., and Maione P. New antiangiogenetic agents and non-small cell lung cancer. Crit Rev Oncol Hematol 60 (2006) 76-86
273. Wilhelm S., Carter C., Lynch M., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5 (2006) 835-844
274. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
275. Cabebe E., and Wakelee H. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. Drugs Today (Barc) 42 (2006) 387-398
276. Manley P.W., Bold G., Bruggen J., et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta 1697 (2004) 17-27
277. Roskoski Jr. R. Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 338 (2005) 1307-1315
278. Hiratsuka S., Nakamura K., Iwai S., et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2 (2002) 289-300
279. Kaplan R.N., Riba R.D., Zacharoulis S., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
280. Kamba T., Tam B.Y., Hashizume H., et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290 (2006) H560-H576
281. von Tell D., Armulik A., and Betsholtz C. Pericytes and vascular stability. Exp Cell Res 312 (2006) 623-629
282. Sanborn R.E., and Sandler A.B. The safety of bevacizumab. Expert Opin Drug Saf 5 (2006) 289-301
283. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
284. Veronese M.L., Mosenkis A., Flaherty K.T., et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24 (2006) 1363-1369
285. Ferrara N., Mass R.D., Campa C., and Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 58 (2007) 491-504
286. Jain R.K., Duda D.G., Clark J.W., and Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3 (2006) 24-40